Loading...
Market
Outcomes of VX-880 Phase 1/2 study endpoints?
4
Vertex Pharmaceuticals•American Diabetes Association•84th Scientific Sessions•Orlando•Day 90•Katherine Lewin
Resolution / Starting Odds
All endpoints met • 33%
Some endpoints met • 33%
No endpoints met • 33%
Vertex Pharmaceuticals clinical trial publications and scientific journals
Story
Vertex Reports Positive Results in Phase 1/2 Study of VX-880 for Type 1 Diabetes at ADA2024 in Orlando
Jun 21, 2024, 08:44 PM
Vertex Pharmaceuticals has announced positive results from its ongoing Phase 1/2 study of VX-880, a stem cell-derived therapy for the treatment of type 1 diabetes. The results, presented at the American Diabetes Association's 84th Scientific Sessions in Orlando, reveal that the therapy can lead to insulin independence and decreased hypoglycemic events. Of the ten patients who completed their 180-day check-in, seven are no longer using insulin. Additionally, all 12 patients who received the full dose of VX-880 demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90, with three achieving insulin independence. Katherine Lewin reported on the findings at ADA2024.
View original story
Similar markets
Exceeds expectations • 25%
Meets expectations • 25%
Below expectations • 25%
Study discontinued • 25%
Exceeds regulatory criteria • 25%
Meets regulatory criteria • 25%
Fails to meet regulatory criteria • 25%
Trial delayed or inconclusive • 25%
Positive efficacy and safety • 25%
Positive efficacy, negative safety • 25%
Negative efficacy • 25%
Inconclusive • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive results • 50%
Negative results • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Safety established • 25%
Preliminary efficacy demonstrated • 25%
Both safety and efficacy demonstrated • 25%
No significant results • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
No Results • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
